BRIEF-Kempharm Announces Initiation Of Phase 2 Clinical Trial Investigating Kp1077 For The Treatment Of Idiopathic Hypersomnia (Ih)

Reuters2022-12-21

Dec 21 (Reuters) - KemPharm Inc :

* KEMPHARM ANNOUNCES INITIATION OF PHASE 2 CLINICAL TRIAL INVESTIGATING KP1077 FOR THE TREATMENT OF IDIOPATHIC HYPERSOMNIA $(IH)$

* INTERIM EFFICACY AND SAFETY DATA EXPECTED AS EARLY AS Q3 2023

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2293343585?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-12-21 20:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2293343585","market":"us","top_or_hot":-1,"title":"BRIEF-Kempharm Announces Initiation Of Phase 2 Clinical Trial Investigating Kp1077 For The Treatment Of Idiopathic Hypersomnia (Ih)","media":"Reuters","content":"<html><body><p>Dec 21 (Reuters) - KemPharm Inc   :</p><p>   * KEMPHARM ANNOUNCES INITIATION OF PHASE 2 CLINICAL TRIAL INVESTIGATING KP1077 FOR THE TREATMENT OF IDIOPATHIC HYPERSOMNIA <a href=\"https://laohu8.com/S/IH\">$(IH)$</a></p><p>   * INTERIM EFFICACY AND SAFETY DATA EXPECTED AS EARLY AS Q3 2023</p><p>Source text for Eikon:    Further company coverage:   </p><p>((Reuters.Briefs@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Kempharm Announces Initiation Of Phase 2 Clinical Trial Investigating Kp1077 For The Treatment Of Idiopathic Hypersomnia (Ih)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Kempharm Announces Initiation Of Phase 2 Clinical Trial Investigating Kp1077 For The Treatment Of Idiopathic Hypersomnia (Ih)\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2022-12-21 20:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>Dec 21 (Reuters) - KemPharm Inc   :</p><p>   * KEMPHARM ANNOUNCES INITIATION OF PHASE 2 CLINICAL TRIAL INVESTIGATING KP1077 FOR THE TREATMENT OF IDIOPATHIC HYPERSOMNIA <a href=\"https://laohu8.com/S/IH\">$(IH)$</a></p><p>   * INTERIM EFFICACY AND SAFETY DATA EXPECTED AS EARLY AS Q3 2023</p><p>Source text for Eikon:    Further company coverage:   </p><p>((Reuters.Briefs@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4510","symbol_name":"在线教育","start_time":0,"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2293343585","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2293343585","pubTimestamp":1671626182,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Dec 21 (Reuters) - KemPharm Inc   :   * KEMPHARM ANNOUNCES INITIATION OF PHASE 2 CLINICAL TRIAL INVE","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4510":"在线教育","BK4563":"昨日强势股","BK4082":"医疗保健设备","BK4139":"生物科技","LABP":"Landos Biopharma, Inc.","BK4085":"互动家庭娱乐","SANA":"Sana Biotechnology, Inc.","BK4007":"制药","CGEM":"Cullinan Therapeutics","LHDX":"Lucira Health, Inc.","BK4196":"保健护理服务","IH":"洪恩"},"translate_title":"简介-Kempharm宣布启动Kp1077治疗特发性睡眠过多(Ih)的2期临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KMPH":0.9,"LABP":0.82,"SANA":0.82,"CGEM":0.82,"LHDX":0.82,"APR":0.82,"IH":1},"content_text":"Dec 21 (Reuters) - KemPharm Inc   :   * KEMPHARM ANNOUNCES INITIATION OF PHASE 2 CLINICAL TRIAL INVESTIGATING KP1077 FOR THE TREATMENT OF IDIOPATHIC HYPERSOMNIA $(IH)$   * INTERIM EFFICACY AND SAFETY DATA EXPECTED AS EARLY AS Q3 2023Source text for Eikon:    Further company coverage:   ((Reuters.Briefs@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2293343585","isCrawlerRequest":true}